State of Arkansas *As Engrossed: xx/xx/xx*

92nd General Assembly A Bill

Regular Session, 2019 SENATE BILL XXX

By: Senators \_\_\_\_\_\_\_, \_\_\_\_\_\_\_\_, \_\_\_\_\_\_\_, \_\_\_\_\_\_\_\_\_, \_\_\_\_\_\_\_\_\_

By: Representatives \_\_\_\_\_\_\_, \_\_\_\_\_\_\_\_, \_\_\_\_\_\_\_\_, \_\_\_\_\_\_\_\_\_

**For An Act To Be Entitled**

AN ACT TO PROVIDE PARITY REPORTING AND IMPLEMENTAITON REQUIREMENTS; AND FOR OTHER PURPOSES

**Subtitle**

TO PROVIDE MEDICATION-ASSISTED TREATMENT REQURIEMENTS

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:

 Section 1. Arkansas Code Title 23, Chapter 99, Subchapter 5 is amended to add additional sections to read as follows:

 23-99-515. Coverage requirements for medications to treat substance use disorders.

 (a) All healthcare insurers that issue or deliver health benefit plans that provide prescription medication benefits for the treatment of substance use disorders shall not impose any prior authorization requirements on any prescription medication approved by the federal Food and Drug Administration (FDA) for the treatment of substance use disorders.

 (b) All healthcare insurers that issue or deliver health benefit plans that provide prescription medication benefits for the treatment of substance use disorders shall not impose any step therapy requirements before the insurer will authorize coverage for a prescription medication approved by the FDA for the treatment of substance use disorders.

 (c) All healthcare insurers that issue or deliver health benefit plans that provide prescription medication benefits for the treatment of substance use disorders shall place all prescription medications approved by the FDA for the treatment of substance use disorders on the lowest tier of the drug formulary developed and maintained by the insurer.

 (d) All healthcare insurers that issue or deliver health benefit plans that provide prescription medication benefits for the treatment of substance use disorders shall not exclude coverage for any prescription medication approved by the FDA for the treatment of substance use disorders and any associated counseling or wraparound services on the grounds that such medications and services were court ordered.

Section 2. Effective date

This act takes effect October 1, 2019.